<DOC>
	<DOCNO>NCT01387022</DOCNO>
	<brief_summary>The HIV/AIDS pandemic remain among investigator greatest public health challenge . In absence effective vaccine , focus shift prevention strategy pre-exposure prophylaxis . Tenofovir , potent activity retroviruses [ 1 ] , develop oral use Viread速 , widely use HIV treatment . The efficacy Viread速 demonstrate treatment-experienced na誰ve patient [ 2,3 ] . In antiretroviral-naive patient , combination tenofovir lamivudine efavirenz classify preferred regimen Department Health Human Services treatment guideline [ 4 ] , adopt South African Department health first line regimen treatment-na誰ve HIV infect patient since April 2010 . The durability antiviral response , favourable resistance profile , daily dosing , excellent long term safety profile tenofovir [ 5 ] , make drug attractive option treatment prevention regimens long half-life [ 6 ] , make ideal choice first antiretroviral drug formulate microbicide gel . The CAPRISA 004 study conduct South Africa test effectiveness safety 1 % tenofovir gel show use tenofovir gel formulation reduce HIV acquisition 39 % overall , 54 % woman high gel adherence [ 7 ] . There concern raise regard use tenofovir PrEP treatment regimen due potential selection viral mutation development resistance patient become HIV-infected PrEP . There study conduct determine whether use tenofovir pre-exposure prophylaxis affect treatment outcomes patient later use tenofovir , part first line ART South Africa . This study aim determine whether prophylactic exposure tenofovir gel alters therapeutic response tenofovir contain antiretroviral regimen .</brief_summary>
	<brief_title>Trial Assess Impact PrEP Tenofovir Gel Efficacy Tenofovir-containing ART Viral Suppression</brief_title>
	<detailed_description>Purpose : To determine whether prophylactic exposure tenofovir gel alters therapeutic response tenofovir contain antiretroviral regimen Study design : Open label , two-arm , randomise control trial Study population : Women become infected HIV participate CAPRISA 004 CAPRISA 008 trial . There 3 study population : Study population 1 : HIV positive woman CAPRISA 004 tenofovir gel arm HIV positive woman clinical trial tenofovir gel provision arm CAPRISA 008 Study population 2 : HIV positive woman placebo arm CAPRISA 004 Study population 3 : HIV positive woman family plan service arm CAPRISA 008 Study site : CAPRISA eThekwini CAPRISA Vulindlela clinic . Study duration : 3 year Study intervention : Enrolled woman initiate assigned antiretroviral therapy regimen reach follow criterion : - reach CD4+ count le 350 cell/mm3 - acquire AIDS define illness - become pregnant - woman three study population become pregnant follow-up initiate assigned treatment regimen , appropriate , prevention mother-to-child transmission HIV . At enrolment woman three study population assign randomly one two follow antiretroviral regimen Intervention Arm : Tenofovir , lamivudine efavirenz Control arm : Zidovudine , lamivudine efavirenz Sample size : The projected sample size 90 woman . The number woman stratum follow : Study population 1 : n = 40 Study population 2 : n = 30 Study population 3 : n = 20 Primary endpoint : The primary endpoint antiretroviral treatment failure rate 12 month . Treatment failure define viral load &gt; 50 copies/ml , antiretroviral regimen change treatment failure death Secondary Endpoints : 1 . Change CD4+ cell count early post-infection timepoint time randomisation 12 , 24 36 month post-randomisation 2 . Tenofovir resistance , define presence K65R , K70E TAMS mutation . 3 . Reported adverse event severity grade 3 4 base DAIDS toxicity grade table 4 . Cellular humoral immune response 5 . Genital viral shedding ( viral load tear flow ) Ancillary Endpoint Mother-to-child HIV transmission rate determine PCR infant 6 week .</detailed_description>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Age 18 year old Previously enrol CAPRISA 004 CAPRISA 008 study placebo active arm Able willing provide inform consent screen , enrol , study Able willing provide adequate locator information study retention purpose Confirmed HIV infection CAPRISA 004 008 trial Agree adhere study visit procedure Currently antiretroviral therapy ( include PMTCT prophylaxis ) Has condition , base opinion Investigator designee , would preclude provision inform consent , make participation study unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Antiretroviral treatment</keyword>
	<keyword>Tenofovir</keyword>
	<keyword>Drug resistance</keyword>
	<keyword>Treatment outcome</keyword>
</DOC>